FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults : vimarsana.com

FSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults

TORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and

Related Keywords

Toronto , Ontario , Canada , Canadian , Zeeshan Saeed , Andrzej Chruscinski , Company Annual Report On Form , Nasdaq , Lucid Psycheceuticals Inc , Biopharma Australia Pty Ltd , Clinical Affairs , Celly Nutrition Corp , Pty Ltd On , Pharma Inc , Strategic Investments Inc , Australia Pty Ltd , Multiple Ascending Dose Study , Healthy Adult , New Chemical Entity , Lucid Psycheceuticals , Celly Nutrition , Investments Inc , Classb Shares , Canadian Securities Administrators , Annual Report , Registration Statement , Executive Co Chairman ,